Bioactivity-guided fractionation of an ethanolic extract of Vitis repens led to the isolation of resveratrol (1), 11-O-acetyl bergenin (2), and stigmast-4-en-3-one (3). The compounds were examined for their in vitro antitrypanosomal activities against trypomastigotes of Trypanosoma evansi. Resveratrol showed antitrypanosomal activity with an IC 50 value of 0.13 µM, whereas 11-O-acetyl bergenin and stigmast-4-en-3-one exhibited IC 50 values of 0.17 and 0.15 µM, respectively.
Trypanosoma evansi is an animal-pathogenic flagellated protozoan parasite that is known to infect a variety of animals, including equines, camels, cattle, buffaloes, goats, sheep and pigs, causing epidemics of a disease known as surra. This disease occurs not only in Africa but also in Central and South America and Asia [1] . The disease is spread by mechanical transmission of infected blood carried by hematophagous insects, especially horseflies (Tabanus spp.) and stable flies (Stomaxys spp.), from one infected host to another [2] . Acutely infected animals die within weeks or months; in contrast, some chronic infections of T. evansi may persist for years [3a] . Human infection by species of Trypanosoma that are parasites of animals is usually impossible because of a trypanolytic factor in human serum. However, it has been found that T. congolese and T. evansi are capable of resistance to human plasma under certain circumstances [3b]. Recently, a human case of trypanosomiasis by T. evansi was identified in India [3c].
Currently, the most commonly used drugs for chemotherapeutic treatment of T. evansi infection are suramin, diminazene aceturate, isometamedium, quinapyramine and cymelarsan. However, several problems are associated with these drugs in many regions, including side effects and ineffectiveness against drug resistant parasites [3d]. Therefore, an alternative, more affordable chemotherapeutic agent, with fewer side effects, is urgently needed for the treatment of T. evansi infection. One possibility of finding such a treatment lies in the use of natural products. The isolated compounds were tested in vitro for their antitrypanosomal activities against T. evansi. The IC 50 value of 1 was 0.13 µM, whereas the values for 2 and 3 were 0.17 and 0.15 µM, respectively. In general, compared with the standard drug diminazene aceturate, with an IC 50 value of 0.0088 µM [7a] , the isolated compounds showed weaker antitrypanosomal activities.
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[α] 28 D -6.9 (c 3.9; MeOH) 1 In vitro test for antitrypanosomal activity: Trypomastigote forms of the parasite were maintained in HMI-9 medium [7b] supplemented with 20% heat-inactivated horse serum (Sigma), as described in detail in a previous paper [7a] . In vitro antitrypanosomal tests were performed in a 96-well culture plate using the crude extracts. The compounds were initially measured and dissolved in dimethyl sulfoxide (100 µL) (DMSO) at a concentration of 10 mg/mL, and ten-fold serial dilutions (take 40 µL) were made with HMI-9 medium (360 µL) in the presence or absence of 0.5% DMSO. An equal volume of the culture liquid of the bloodstream trypomastigotes form of T. evansi (400 µL) (5 х10 -4 ) was added to the above-mentioned solution. Then, 200 µL of the culture medium of T. evansi in the presence of each compound was incubated in a 96-well plate. The experiment was tested in triplicate. The plates were incubated at 37°C in a 5% CO 2 atmosphere for 72 h. The activities of the compounds were determined by counting the number of motile parasites using a Neubauer haemocytometer [0.100 mm, Tiefe depth profondeur, and 0.0025 mm 2, Hirschmann Laborgrate]. To determine the 50% inhibitory concentration (IC 50 ) on parasite growth for each compound, triplicate assays of the compounds at each concentration were prepared. The IC 50 value was calculated by computerized probit analysis (http://chiryo.phar.nagoyacu.ac.jp/javastat/Graded50-e.htm#).
